The FDA expects organizations to have full visibility and control over their processes

Publisher: Dassault Systèmes BIOVIA

Access this content

Your content has been opened.

Please verify you are a human before downloading this content.

The FDA expects organizations to have full visibility and control over their processes has been emailed to . Entered the wrong email?

Don't see the content in your inbox?
Make sure to check your spam and other messages folders.

Can't get to your email right now?

To complete your registration and access this content, enter the sign-in code sent to your email.

Please enter a valid verification code.

Code sent to:

Also, remember to check in your spam, promotions, and other folders.


Register to access this content


By accessing content on the Pharmaceutical Manufacturing Resource Directory you agree to our Terms of Service and Privacy Policy; and, you acknowledge that your information may be shared with the content publisher.

The FDA expects organizations to have full visibility and control over their processes

Expectations include: • Understanding products and processes in order to implement Quality by Design (QbD) into product development • Delivery of quality metrics for risk-based inspection schedules as proposed by a new quality metrics program • Shared responsibility for products manufactured by their Contract Manufacturing Organizations (CMOs) • Drive improvements in manufacturing technology, product quality and safety - reducing recalls and mitigating drug shortages